Bayer: presents data for Parkinson's disease

(CercleFinance.com) - Bayer and BlueRock Therapeutics have announced positive 24-month data from exPDite, a Phase 1 clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease.


'Bemdaneprocel is the most clinically advanced investigational cell therapy in the US for the treatment of people with Parkinson's disease' says the group.

The 24-month data will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Philadelphia on September 28, 2024.

' The completed study demonstrates that the transplanted cells survive and that there are early signs that bemdaneprocel can potentially help patients better control their motor symptoms. These are exciting results that warrant further exploration in a forthcoming placebo-controlled study phase' said Claire Henchcliffe, MD, Chair of the Department of Neurology at the UCI School of Medicine at the University of California, Irvine and one of the study's principal investigators.

Copyright (c) 2024 CercleFinance.com. All rights reserved.